Mortality of lung cancer patients versus other cancer patients infected with COVID-19: A systematic review and meta-analysis_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

HONG Ziqiang ^1,2 , JIN Dacheng ² , BAI Xiangdou ^1,2 , HUANG Daxin ^1,2 , CUI Baiqiang ^1,2 ,  GOU Yunjiu ²

1. The First Clinical Department of Gansu University of Traditional Chinese Medicine, Lanzhou, 730000, P. R. China;
2. Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou, 730000, P. R. China;

Corresponding?author：

GOU Yunjiu, Email: gouyunjiu@163.com

Keywords：

Novel coronavirus; lung cancer; cancer; mortality; systematic review/meta-analysis

DOI：

10.7507/1007-4848.202201052

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To compare the mortality in lung cancer patients infected with coronavirus disease 2019 (COVID-19) versus other cancer patients infected with COVID-19. Methods A computer search of PubMed, EMbase, The Cochrane Library, Web of Science, Wanfang database, VIP database and CNKI database was conducted to compare the mortality of lung cancer and other cancers patients infected with COVID-19 from the inception to December 2021. Two thoracic surgeons independently screened the literature, extracted data, and then cross-checked the literature. After evaluating the quality of the included literature, a meta-analysis was performed on the literature using Review Manager 5.4 software. Results A total of 12 retrospective cohort studies were included, covering 3 065 patients infected with COVID-19, among whom 340 patients suffered from lung cancer and the remaining 2 725 patients suffered from other cancers. Meta-analysis results showed that the lung cancer patients infected with COVID-19 had a higher mortality (OR=1.58, 95%CI 1.24 to 2.02, P<0.001). Subgroup analysis results showed that the mortality of two groups of patients in our country was not statistically different (OR=0.90, 95%CI 0.49 to 1.65, P=0.72). Whereas, patients with lung cancer had a higher mortality than those with other cancers in other countries (Brazil, Spain, USA, France, Italy, UK, Netherlands) (OR=1.78, 95%CI 1.37 to 2.32, P<0.001). Conclusion There is a negligible difference in mortality between lung cancer and other cancers patients who are infected with COVID-19 in our country; while a higher mortality rate is found in lung cancer patients in other countries. Consequently, appropriate and positive prevention methods should be taken to reduce the risk of infecting COVID-19 in cancer patients and to optimize the management of the infected population.

Citation： HONG Ziqiang, JIN Dacheng, BAI Xiangdou, HUANG Daxin, CUI Baiqiang, GOU Yunjiu. Mortality of lung cancer patients versus other cancer patients infected with COVID-19: A systematic review and meta-analysis. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30(2): 179-184. doi: 10.7507/1007-4848.202201052 Copy

1.	Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, et al. Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Clin Microbiol Rev, 2021, 34(3): e00228-220.
2.	de Joode K, Dumoulin DW, Engelen V, et al. Impact of the coronavirus disease 2019 pandemic on cancer treatment: The patients' perspective. Eur J Cancer, 2020, 136: 132-139.
3.	王衛東, 馮梅, 郎錦義. 新型冠狀病毒肺炎疫期腫瘤患者防控的挑戰與對策. 腫瘤預防與治療, 2020, 33(2): 87-90.
4.	Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol, 2020, 31(7): 894-901.
5.	Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol, 2020, 21(3): 335-337.
6.	Zhang H, Wang L, Chen Y, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer, 2020, 126(17): 4023-4031.
7.	Provencio M, Mazarico Gallego JM, Calles A, et al. Lung cancer patients with COVID-19 in Spain: GRAVID study. Lung Cancer, 2021, 157: 109-115.
8.	Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. JNCI Cancer Spectr, 2021, 5(2): pkaa102.
9.	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
10.	Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol, 2020, 21(7): 904-913.
11.	de Melo AC, Thuler LCS, da Silva JL, et al. Cancer in patients with COVID-19: A report from the Brazilian National Cancer Institute. PLoS One, 2020, 15(10): e0241261.
12.	Yarza R, Bover M, Paredes D, et al. SARS-CoV-2 infection in cancer patients undergoing active treatment: Analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer, 2020, 135: 242-250.
13.	Yu J, Ouyang W, Chua MLK, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol, 2020, 6(7): 1108-1110.
14.	Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov, 2020, 10(7): 935-941.
15.	Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov, 2020, 10(6): 783-791.
16.	Basse C, Diakite S, Servois V, et al. Characteristics and outcome of SARS-CoV-2 infection in cancer patients. JNCI Cancer Spectr, 2021, 5(1): pkaa090.
17.	Stroppa EM, Toscani I, Citterio C, et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future Oncol, 2020, 16(20): 1425-1432.
18.	Joharatnam-Hogan N, Hochhauser D, Shiu KK, et al. Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: A multi-centre North London experience. Ther Adv Med Oncol, 2020, 12: 1758835920956803.
19.	Benderra MA, Aparicio A, Leblanc J, et al. Clinical characteristics, care trajectories and mortality rate of SARS-CoV-2 infected cancer patients: A multicenter cohort study. Cancers (Basel), 2021, 13(19): 4749.
20.	de Joode K, Tol J, Hamberg P, et al. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: An update from the Dutch Oncology COVID-19 Consortium. Eur J Cancer, 2022, 160: 261-272.
21.	Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020, 5(7): 811-818.
22.	Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int J Infect Dis, 2020, 94: 91-95.
23.	The Lancet Oncology. COVID-19: Global consequences for oncology. Lancet Oncol, 2020, 21(4): 467.
24.	Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Ann Oncol, 2020, 31(10): 1386-1396.
25.	魏秋華, 任哲. 2019新型冠狀病毒感染的肺炎疫源地消毒措施. 中國消毒學雜志, 2020, 37(1): 59-62.

1. Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, et al. Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Clin Microbiol Rev, 2021, 34(3): e00228-220.
2. de Joode K, Dumoulin DW, Engelen V, et al. Impact of the coronavirus disease 2019 pandemic on cancer treatment: The patients' perspective. Eur J Cancer, 2020, 136: 132-139.
3. 王衛東, 馮梅, 郎錦義. 新型冠狀病毒肺炎疫期腫瘤患者防控的挑戰與對策. 腫瘤預防與治療, 2020, 33(2): 87-90.
4. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol, 2020, 31(7): 894-901.
5. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol, 2020, 21(3): 335-337.
6. Zhang H, Wang L, Chen Y, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer, 2020, 126(17): 4023-4031.
7. Provencio M, Mazarico Gallego JM, Calles A, et al. Lung cancer patients with COVID-19 in Spain: GRAVID study. Lung Cancer, 2021, 157: 109-115.
8. Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. JNCI Cancer Spectr, 2021, 5(2): pkaa102.
9. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
10. Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol, 2020, 21(7): 904-913.
11. de Melo AC, Thuler LCS, da Silva JL, et al. Cancer in patients with COVID-19: A report from the Brazilian National Cancer Institute. PLoS One, 2020, 15(10): e0241261.
12. Yarza R, Bover M, Paredes D, et al. SARS-CoV-2 infection in cancer patients undergoing active treatment: Analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer, 2020, 135: 242-250.
13. Yu J, Ouyang W, Chua MLK, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol, 2020, 6(7): 1108-1110.
14. Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov, 2020, 10(7): 935-941.
15. Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov, 2020, 10(6): 783-791.
16. Basse C, Diakite S, Servois V, et al. Characteristics and outcome of SARS-CoV-2 infection in cancer patients. JNCI Cancer Spectr, 2021, 5(1): pkaa090.
17. Stroppa EM, Toscani I, Citterio C, et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future Oncol, 2020, 16(20): 1425-1432.
18. Joharatnam-Hogan N, Hochhauser D, Shiu KK, et al. Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: A multi-centre North London experience. Ther Adv Med Oncol, 2020, 12: 1758835920956803.
19. Benderra MA, Aparicio A, Leblanc J, et al. Clinical characteristics, care trajectories and mortality rate of SARS-CoV-2 infected cancer patients: A multicenter cohort study. Cancers (Basel), 2021, 13(19): 4749.
20. de Joode K, Tol J, Hamberg P, et al. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: An update from the Dutch Oncology COVID-19 Consortium. Eur J Cancer, 2022, 160: 261-272.
21. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020, 5(7): 811-818.
22. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int J Infect Dis, 2020, 94: 91-95.
23. The Lancet Oncology. COVID-19: Global consequences for oncology. Lancet Oncol, 2020, 21(4): 467.
24. Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Ann Oncol, 2020, 31(10): 1386-1396.
25. 魏秋華, 任哲. 2019新型冠狀病毒感染的肺炎疫源地消毒措施. 中國消毒學雜志, 2020, 37(1): 59-62.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Mortality of lung cancer patients versus other cancer patients infected with COVID-19: A systematic review and meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content